# Use of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis

Submission date	Recruitment status	Prospectively registered
29/09/2006	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
29/09/2006	Completed	Results
Last Edited	Condition category	Individual participant data
17/05/2017	Haematological Disorders	Record updated in last year

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr A Chesser

#### Contact details

Consultant Nephrologist
Renal Office
Royal London Hospital
Whitechapel
London
United Kingdom
E1 1BB
+44 (0)20 7377 7366
alistair.chesser@bartsandthelondon.nhs.uk

# Additional identifiers

#### **EudraCT/CTIS** number

#### **IRAS** number

ClinicalTrials.gov number

# Secondary identifying numbers

N0205168926

# Study information

#### Scientific Title

Use of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis

### **Study objectives**

To quantify the effect of on-line mid-dilution haemodiafiltration on the use of erythropoietin for anaemia management in patients with end-stage renal disease compared to the technique of conventional haemodialysis.

## Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

# Study design

Randomised controlled trial

# Primary study design

Interventional

# Secondary study design

Randomised controlled trial

# Study setting(s)

Hospital

# Study type(s)

Treatment

# Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

# Health condition(s) or problem(s) studied

Anaemia

#### Interventions

## Not provided at time of registration

## Intervention Type

Drug

#### **Phase**

Not Applicable

# Drug/device/biological/vaccine name(s)

Erythropoietin

#### Primary outcome measure

Control of haemoglobin and use of erythropoietin

#### Secondary outcome measures

Not provided at time of registration

## Overall study start date

27/07/2005

#### Completion date

31/07/2007

# **Eligibility**

## Key inclusion criteria

Not provided at time of registration

#### Participant type(s)

**Patient** 

#### Age group

**Not Specified** 

#### Sex

**Not Specified** 

# Target number of participants

80

#### Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

27/07/2005

#### Date of final enrolment

31/07/2007

# **Locations**

#### Countries of recruitment

England

**United Kingdom** 

Study participating centre Royal London Hospital London United Kingdom E1 1BB

# Sponsor information

#### Organisation

Record Provided by the NHSTCT Register - 2006 Update - Department of Health (UK)

#### Sponsor details

The Department of Health, Richmond House, 79 Whitehall London United Kingdom SW1A 2NL +44 (0)20 7307 2622 dhmail@doh.gsi.org.uk

#### Sponsor type

Government

#### Website

http://www.dh.gov.uk/Home/fs/en

# Funder(s)

# Funder type

Government

#### Funder Name

Barts and The London NHS Trust (UK)

## Funder Name

NHS R&D Support Funding (UK)

# **Results and Publications**

**Publication and dissemination plan**Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration